CD19 and neoplasm: In preclinical studies, iCARs demonstrated reduced cytokine production and cytotoxicity when co-cultured with cells expressing both tumor and healthy antigens, such as CD19 and PSMA, respectively, compared to cells expressing only the tumor antigen (CD19).